Sharma Mahesh S, Webber Steven A, Morell Victor O, Gandhi Sanjiv K, Wearden Peter D, Buchanan Julianne R, Kormos Robert L
Department of Cardiothoracic Surgery, The University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Ann Thorac Surg. 2006 Sep;82(3):926-32. doi: 10.1016/j.athoracsur.2006.02.087.
Mechanical circulatory support using ventricular assist devices (VADs) is a life-saving option for children in heart failure refractory to maximal medical management. The aim of this study was to evaluate the efficacy of standard adult VADs in adolescents and children as well as report our early experience with miniaturized VADs in small children.
A 15-year retrospective review was performed on all patients younger than 18 years of age undergoing insertion of a pulsatile VAD at our institution.
Eighteen patients underwent VAD placement during the study period. The mean age was 12 (range, 6 months to 18 years), with a mean body surface area of 1.48 (range, 0.25 to 2.3 m2). Diagnoses included dilated cardiomyopathy (n = 15), myocarditis (n = 2), and postcardiotomy ventricular failure (n = 1). Ten children underwent insertion of biventricular VADs, and 8 had implantation of left ventricular VADs. The mean support duration was 57 days (range, 2 to 175 days). Complications included bleeding requiring reoperation (n = 4), stroke (n = 5), and device-related infection (n = 2). Outcomes of VAD support were as follows: VAD explantation in 1 case, death while receiving mechanical support in 3 patients, and successful transplantation in 14 patients (77%). Survival at 6 months after orthotopic heart transplantation was 93% with 1-year and 5-year survival rates of 83%.
Currently available VADs are applicable for use as a bridge to orthotopic heart transplantation or in rare instances for myocardial recovery. The increasing accessibility of miniaturized devices allow for long-term support in smaller children and infants while awaiting orthotopic heart transplantation. Although the perioperative morbidity and mortality of VAD placement is not insignificant, survival for those who receive a heart transplant is excellent.
对于经最大程度药物治疗仍难治的心力衰竭儿童,使用心室辅助装置(VAD)进行机械循环支持是一种挽救生命的选择。本研究的目的是评估标准成人VAD在青少年和儿童中的疗效,并报告我们在幼儿中使用小型VAD的早期经验。
对在我们机构接受搏动性VAD植入的所有18岁以下患者进行了为期15年的回顾性研究。
在研究期间,18例患者接受了VAD植入。平均年龄为12岁(范围为6个月至18岁),平均体表面积为1.48(范围为0.25至2.3平方米)。诊断包括扩张型心肌病(n = 15)、心肌炎(n = 2)和心脏手术后心室衰竭(n = 1)。10名儿童接受了双心室VAD植入,8名接受了左心室VAD植入。平均支持时间为57天(范围为2至175天)。并发症包括需要再次手术的出血(n = 4)、中风(n = 5)和与装置相关的感染(n = 2)。VAD支持的结果如下:1例VAD取出,3例患者在接受机械支持时死亡,14例患者成功移植(77%)。原位心脏移植后6个月的生存率为93%,1年和5年生存率分别为83%。
目前可用的VAD可作为原位心脏移植的桥梁,或在罕见情况下用于心肌恢复。小型化装置的可及性增加使得在更小的儿童和婴儿等待原位心脏移植时能够进行长期支持。尽管VAD植入的围手术期发病率和死亡率并不低,但接受心脏移植者的生存率很高。